Short Interest in Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Expands By 64.7%

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) was the target of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,310,000 shares, an increase of 64.7% from the September 30th total of 2,010,000 shares. Currently, 15.1% of the company’s stock are short sold. Based on an average daily trading volume, of 571,200 shares, the days-to-cover ratio is currently 5.8 days.

Hedge funds have recently made changes to their positions in the business. Deltec Asset Management LLC lifted its stake in Adamas Pharmaceuticals by 4.4% in the 3rd quarter. Deltec Asset Management LLC now owns 574,886 shares of the specialty pharmaceutical company’s stock worth $2,941,000 after purchasing an additional 24,050 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Adamas Pharmaceuticals by 10.3% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 46,928 shares of the specialty pharmaceutical company’s stock worth $291,000 after purchasing an additional 4,381 shares in the last quarter. Fisher Asset Management LLC lifted its stake in Adamas Pharmaceuticals by 19.6% in the 2nd quarter. Fisher Asset Management LLC now owns 138,724 shares of the specialty pharmaceutical company’s stock worth $860,000 after purchasing an additional 22,705 shares in the last quarter. Advisor Group Inc. lifted its stake in Adamas Pharmaceuticals by 53.4% in the 2nd quarter. Advisor Group Inc. now owns 11,200 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 3,900 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its stake in Adamas Pharmaceuticals by 63.8% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 15,400 shares of the specialty pharmaceutical company’s stock worth $91,000 after purchasing an additional 6,000 shares in the last quarter. Institutional investors and hedge funds own 63.22% of the company’s stock.

ADMS has been the topic of a number of research reports. ValuEngine raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Northland Securities reaffirmed a “buy” rating and set a $15.00 price target on shares of Adamas Pharmaceuticals in a research note on Friday. JMP Securities dropped their price target on Adamas Pharmaceuticals to $16.00 and set an “outperform” rating on the stock in a research note on Friday. Cowen set a $5.00 price target on Adamas Pharmaceuticals and gave the stock a “hold” rating in a research note on Friday, August 9th. Finally, Zacks Investment Research downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 16th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company’s stock. Adamas Pharmaceuticals has a consensus rating of “Hold” and an average target price of $17.02.

Shares of Adamas Pharmaceuticals stock traded down $0.25 on Monday, hitting $5.38. The company had a trading volume of 27,967 shares, compared to its average volume of 491,521. The stock has a market capitalization of $119.97 million, a price-to-earnings ratio of -1.10 and a beta of 1.61. Adamas Pharmaceuticals has a 1 year low of $3.35 and a 1 year high of $13.25. The stock has a 50 day moving average of $4.71 and a 200-day moving average of $5.53. The company has a debt-to-equity ratio of 3.05, a quick ratio of 7.05 and a current ratio of 7.27.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.09). The company had revenue of $13.93 million during the quarter, compared to analysts’ expectations of $14.36 million. Adamas Pharmaceuticals had a negative return on equity of 149.97% and a negative net margin of 241.41%. Equities analysts anticipate that Adamas Pharmaceuticals will post -3.74 earnings per share for the current year.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

See Also: Differences Between Momentum Investing and Long Term Investing

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.